Hangzhou Jiuyuan Gene Engineering (SEHK:2566) - Stock Price, News & Analysis

2566 Stock Overview

Hangzhou Jiuyuan Gene Engineering Co., Ltd. More details

2566 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Hangzhou Jiuyuan Gene Engineering Co., Ltd. Competitors

Ocumension Therapeutics

SEHK:1477

HK$4.3b

Dawnrays Pharmaceutical (Holdings)

SEHK:2348

HK$1.8b

Jacobson Pharma

SEHK:2633

HK$1.6b

JBM (Healthcare)

SEHK:2161

HK$1.5b

Price History & Performance

Summary of all time highs, changes and price drops for Hangzhou Jiuyuan Gene Engineering
Historical stock prices
Current Share Price	HK$12.02
52 Week High	HK$0
52 Week Low	HK$0
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	2566	HK Pharmaceuticals	HK Market
7D	n/a	0.3%	-2.8%
1Y	n/a	-12.3%	10.0%

Return vs Industry: Insufficient data to determine how 2566 performed against the Hong Kong Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 2566 performed against the Hong Kong Market.

Price Volatility

Is 2566's price volatile compared to industry and market?
2566 volatility
2566 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

Stable Share Price: 2566's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: Insufficient data to determine 2566's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	n/a	Hang Fu	www.china-gene.com

Hangzhou Jiuyuan Gene Engineering Co., Ltd. engages in the research, development, production and sales of biopharmaceutical products and medical devices. It offers Guyoudao, a recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair product; Jilifen, a Human granulocyte colony stimulating factor injection for neutropenia; and Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia.

Hangzhou Jiuyuan Gene Engineering Co., Ltd. Fundamentals Summary

How do Hangzhou Jiuyuan Gene Engineering's earnings and revenue compare to its market cap?
2566 fundamental statistics
Market cap	HK$2.95b
Earnings (TTM)	HK$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 2566 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2566 income statement (TTM)
Revenue	HK$0
Cost of Revenue	HK$0
Gross Profit	HK$0
Other Expenses	HK$0
Earnings	HK$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 2566 perform over the long term?

See historical performance and comparison